Kaplan-Meier survival analysis showed a significant increase in the risk of MACCE inpatients with nondiabetes STEMI having plasma MIF levels ≥ 52.8 ng/mL at presentation (P = 0.006, Figure 3(a)); in the diabetes STEMI group, patients with MIF levels ≥ 55.7 ng/mL had no significant difference in the risk of MACCE compared to those with low MIF levels (P = 0.121, Figure 3(b)). This evidence concerns the gene MIF and diabetes mellitus.